Cellectis (CLLS) Net Income Growth (3y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 32.79% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 60.43% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -46.86% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 13.80% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 19.97% |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -3.84% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 47.10% |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - | -64.08% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -64.08% |
| Dec 31, 2025 | -234.24% |
| Sep 30, 2025 | 74.51% |
| Jun 30, 2025 | 191.90% |
| Dec 31, 2024 | -91.10% |
| Sep 30, 2024 | 28.25% |
| Jun 30, 2023 | 33.81% |
| Mar 31, 2023 | -32.49% |
| Dec 31, 2022 | 57.79% |
| Sep 30, 2022 | 40.13% |
| Jun 30, 2022 | 76.74% |
| Dec 31, 2021 | 34.90% |
| Sep 30, 2021 | -13.60% |
| Jun 30, 2021 | -19.99% |
| Dec 31, 2020 | -12.15% |
| Sep 30, 2020 | -4.53% |
| Jun 30, 2020 | -18.53% |
| Mar 31, 2020 | 39.75% |
| Dec 31, 2019 | -23.73% |
| Sep 30, 2019 | -27.37% |
| Jun 30, 2019 | -45.86% |
| Mar 31, 2019 | -0.89% |
| Jun 30, 2018 | -17.42% |
| Mar 31, 2018 | -83.66% |